Patent · US Active

Crystalline forms of a MAGL inhibitor

US12378219B2 · kind B2 · utility

0Cited by

6References

9Claims

0Family size

Assignee

H. LUNDBECK A/S · DK

Inventors

Thomas Vetter · Copenhagen, DK
John J. M. Wiener · San Diego, US
Cheryl A. Grice · Carlsbad, US
Daniel J. Buzard · San Diego, US
Justin S. Cisar · San Diego, US
Olivia D. Weber · San Diego, US
Amy Allan · San Diego, US
Nicholas Brian Raffaele · San Diego, US
Jeanne V. Moody · San Diego, US
Michael B. Shaghafi · San Diego, US

Key dates

Filing date	May 3, 2023
Grant date	Aug 5, 2025
Priority date	—
Expiry date	Jul 10, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.